The Utility of 68Ga-PSMA PET/CT in Poorly Differentiated Metastatic Prostate Cancer.


Demirkol M. O. , Kiremit M. C. , Acar O., Ucar B., Saglican Y.

Clinical nuclear medicine, vol.42, no.5, pp.403-405, 2017 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 42 Issue: 5
  • Publication Date: 2017
  • Doi Number: 10.1097/rlu.0000000000001617
  • Title of Journal : Clinical nuclear medicine
  • Page Numbers: pp.403-405

Abstract

We aimed to emphasize how useful PSMA PET/CT findings can be while trying to restage prostate cancer after radical prostatectomy in the presence of low prostate-specific antigen values. A 64-year-old man with pT3b N1 M0 Gleason 7 adenocarcinoma of the prostate presented 5 years postoperatively with a palpable axillary mass, whereas his prostate-specific antigen was 0.08 ng/mL. Conventional imaging studies and histopathologic findings of the axillary mass biopsy revealed inconclusive results. Ga-68-PSMA PET/CT demonstrated PSMA-positive metastatic lesions, the largest one being located in the right axilla. This finding confirmed metastatic poorly differentiated prostate cancer, and androgen deprivation therapy was initiated.